; and (ii) the comparative effectiveness of a drug or device relative to others products, other health care interventions, program and quality improvement interventions, or no intervention. (d) Distribution Information pursuant to subsection (b) may be distributed proactively through written or oral means, or other information platforms, to a health care provider, payor, formulary committee, or other similar entity carrying out responsibilities for making drug coverage, reimbursement, or usage decisions on a population basis. (e) Coverage not excluded The distribution of information that otherwise meets the requirements of this section shall not fail to meet the requirements of subsection (a) because the manufacturer or distributor of the drug or device about which information is being distributed has— (1) knowledge that such drug or device is being used by patients or health care practitioners in a manner not described in any labeling of the drug or device, as applicable; or (2) objective or subjective intent that such drug or device be used in a manner inconsistent with any labeling, as applicable, of such drug or device. (f) Rule of construction Nothing in this section shall be construed— (1) to limit communication not specifically permitted by this section